iShares Biotechnology ETF
790 hedge funds and large institutions have $3.94B invested in iShares Biotechnology ETF in 2025 Q2 according to their latest regulatory filings, with 56 funds opening new positions, 137 increasing their positions, 347 reducing their positions, and 82 closing their positions.
New
Increased
Maintained
Reduced
Closed
more call options, than puts
Call options by funds: $ | Put options by funds: $
more ownership
Funds ownership: →
less capital invested
Capital invested by funds: $ → $
less funds holding
Funds holding: →
13% less funds holding in top 10
Funds holding in top 10: 8 → 7 (-1)
32% less first-time investments, than exits
New positions opened: 56 | Existing positions closed: 82
61% less repeat investments, than reductions
Existing positions increased: 137 | Existing positions reduced: 347
Holders
790
Holding in Top 10
7
Calls
$216M
Puts
$168M
Top Buyers
| 1 | +$247M | |
| 2 | +$110M | |
| 3 | +$103M | |
| 4 |
JP Morgan Chase
New York
|
+$44.9M |
| 5 |
ERSOT
Employees Retirement System of Texas
Austin,
Texas
|
+$25M |
Top Sellers
| 1 | -$105M | |
| 2 | -$78.3M | |
| 3 | -$57.2M | |
| 4 |
Barclays
London,
United Kingdom
|
-$41.8M |
| 5 |
Two Sigma Investments
New York
|
-$35.5M |
